The results of a phase I / II study of INTUVAX® indicates that the vaccine can enhance the body’s immune system and thereby prolong survival in renal cancer. Additionally observed signs of synergistic effect with tyrosine kinase inhibitors – a different kind of drugs against tumor diseases. No confirmed vaccine-related adverse events were recorded.
Mendus
IMendus (publ) develops vaccines for the treatment of cancer. The company’s most advanced project is INTUVAX® for the treatment of kidney cancer. The project portfolio further four projects against various tumor diseases, including liver cancer.
